Accessibility Menu
DarioHealth Stock Quote

DarioHealth (NASDAQ: DRIO)

$10.26
(-12.7%)
-1.49
Price as of November 13, 2025, 12:36 p.m. ET

KEY DATA POINTS

Current Price
$10.26
Daily Change
(-12.7%) $1.49
Day's Range
$9.01 - $11.50
Previous Close
$11.75
Open
$11.22
Beta
1.23
Volume
28,052
Average Volume
66,982
Market Cap
79.5M
Market Cap / Employee
$11.75M
52wk Range
$5.94 - $31.00
Revenue
-
Gross Margin
0.55%
Dividend Yield
N/A
EPS
-$19.89
CAPs Rating
-
Industry
Health Care Technology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

DarioHealth Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
DRIO-32.08%-95.52%-46.25%-100%
S&P+14.49%+91.09%+13.83%+337%

DarioHealth Company Info

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

News & Analysis

No results found

No news articles found for DarioHealth.

Financial Health

General

Q2 2025YOY Change
Revenue$5.37M-14.2%
Gross Profit$2.96M7.5%
Gross Margin55.21%11.1%
Market Cap$30.47M-13.0%
Market Cap / Employee$0.15M0.0%
Employees202-26.8%
Net Income-$7.42M-120.2%
EBITDA-$8.40M41.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$22.17M-6.8%
Accounts Receivable$2.56M-62.0%
Inventory4.6-10.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$31.11M26.7%
Short Term Debt$0.51M-91.6%

Ratios

Q2 2025YOY Change
Return On Assets-31.55%-1.1%
Return On Invested Capital-70.19%12.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$6.08M46.7%
Operating Free Cash Flow-$6.03M46.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.600.420.350.486.06%
Price to Sales1.961.121.031.22-50.52%
Price to Tangible Book Value-36.43-25.57-112.72-430.9386.97%
Enterprise Value to EBITDA-5.99-3.69-3.84-5.0833.44%
Return on Equity-50.9%-46.1%-42.6%-55.1%10.52%
Total Debt$30.49M$30.19M$30.34M$31.62M3.23%

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.